1. Home
  2. VSTS vs GERN Comparison

VSTS vs GERN Comparison

Compare VSTS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VSTS
  • GERN
  • Stock Information
  • Founded
  • VSTS 1936
  • GERN 1990
  • Country
  • VSTS United States
  • GERN United States
  • Employees
  • VSTS N/A
  • GERN N/A
  • Industry
  • VSTS
  • GERN Biotechnology: Pharmaceutical Preparations
  • Sector
  • VSTS
  • GERN Health Care
  • Exchange
  • VSTS Nasdaq
  • GERN Nasdaq
  • Market Cap
  • VSTS 763.0M
  • GERN 853.5M
  • IPO Year
  • VSTS N/A
  • GERN 1996
  • Fundamental
  • Price
  • VSTS $6.22
  • GERN $1.51
  • Analyst Decision
  • VSTS Hold
  • GERN Buy
  • Analyst Count
  • VSTS 4
  • GERN 7
  • Target Price
  • VSTS $11.75
  • GERN $4.17
  • AVG Volume (30 Days)
  • VSTS 2.0M
  • GERN 10.4M
  • Earning Date
  • VSTS 08-06-2025
  • GERN 08-07-2025
  • Dividend Yield
  • VSTS 1.74%
  • GERN N/A
  • EPS Growth
  • VSTS N/A
  • GERN N/A
  • EPS
  • VSTS N/A
  • GERN N/A
  • Revenue
  • VSTS $2,731,558,000.00
  • GERN $116,293,000.00
  • Revenue This Year
  • VSTS N/A
  • GERN $160.12
  • Revenue Next Year
  • VSTS $0.36
  • GERN $55.01
  • P/E Ratio
  • VSTS N/A
  • GERN N/A
  • Revenue Growth
  • VSTS N/A
  • GERN 22264.04
  • 52 Week Low
  • VSTS $5.20
  • GERN $1.17
  • 52 Week High
  • VSTS $17.83
  • GERN $5.06
  • Technical
  • Relative Strength Index (RSI)
  • VSTS 46.64
  • GERN 51.44
  • Support Level
  • VSTS $5.62
  • GERN $1.42
  • Resistance Level
  • VSTS $6.03
  • GERN $1.57
  • Average True Range (ATR)
  • VSTS 0.20
  • GERN 0.09
  • MACD
  • VSTS 0.07
  • GERN -0.01
  • Stochastic Oscillator
  • VSTS 59.65
  • GERN 35.19

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: